General Information of the Protein
Protein ID
PT00883
Protein Name
Angiopoietin-1 receptor
Secondarily
Protein Name
Endothelial tyrosine kinase
Tunica interna endothelial cell kinase
Tyrosine kinase with Ig and EGF homology domains-2
Tyrosine-protein kinase receptor TEK
Tyrosine-protein kinase receptor TIE-2
p140 TEK
Gene Name
TEK
Secondarily
Gene Name
TIE2
VMCM
VMCM1
Sequence
MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRTCEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNEACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIQRMTPKIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGTLALNRKVKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLYLAIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQFIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRLPVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRLEKPLNCDDEVYDLMRQCWREKPYERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
TK protein kinase group
>
Tyrosine protein kinase Tie family
Function
Tyrosine-protein kinase that acts as a cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of pro-inflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.
    Show/Hide
Uniprot ID
Primary ID:
Q02763

Secondarily ID:
A8K6W0
B4DH20
B4DHD3
D3DRK5
E7EWI2
Q5TCU2
Q8IV34
    Show/Hide
Ensembl ID
ENSG00000120156
HGNC ID
HGNC:11724
Subcellular Location
Cell membrane
Cell junction
Cell junction
Focal adhesion
Cytoplasm
Cytoskeleton
Secreted
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000077 , Ba/F3
Compound ID Compound Name Compound Formula
CP0019908
BDBM50242742
   Show/Hide
C30H40ClN7O3S
 1
1
IC50 = 1167 nM
   TI
   LI
   LO
   TS
CP0661487
3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea monophosphate
   Show/Hide
C26H34Cl2N7O7P
 1
1
IC50 = 2051 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0019908
BDBM50242742
   Show/Hide
C30H40ClN7O3S
 3
1 EC50 = 1167 nM
2 IC50 = 12 nM
3 Kd = 46 nM
CP0098898
3-isopropyl-N-(4-methyl-3-(3-(2-(methylamino)pyridin-4-yl)pyridin-2-yloxy)phenyl)benzamide
   Show/Hide
C28H28N4O2
 1
1 IC50 = 1 nM
CP0177211
3-isopropyl-N-(4-methyl-3-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)phenyl)benzamide
   Show/Hide
C26H26N6O2
 1
1 IC50 = 1 nM
CP0111780
4-Methyl-3-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)-N-(3-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C25H20F3N5O2
 2
1 IC50 = 1 nM
2 IC50 < 1 nM
CP0059426
3-{4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-1-[2-fluoro-5-(trifluoromethyl)phenyl]urea
   Show/Hide
C27H19F4N5O3
 2
1 IC50 = 1.995 nM
2 IC50 = 2 nM
CP0111772
2-(Methylamino)pyrimidine 58
   Show/Hide
C30H31F4N7O2
 1
1 IC50 = 4 nM
CP0154852
N-(5-Cyclohexyl-2-methoxyphenyl)-4-methyl-3-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)benzamide
   Show/Hide
C31H33N5O3
 1
1 IC50 = 4 nM
CP0026519
(S)-5-(2-(2-Aminopyrimidin-5-yl)ethynyl)-N-(2-(3-(dimethylamino)piperidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluorobenzamide
   Show/Hide
C27H26F4N6O
 1
1 IC50 = 5 nM
CP0203349
3-isopropyl-N-(3-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)phenyl)benzamide
   Show/Hide
C25H24N6O2
 1
1 IC50 = 6 nM
CP0162636
2-(Methylamino)triazine 64
   Show/Hide
C31H37FN8O2
 1
1 IC50 = 6 nM
CP0177210
N-[4-methyl-3-[3-[4-(methylamino)-1,3,5-triazin-2-yl]pyridin-2-yl]oxyphenyl]-3-(trifluoromethoxy)benzamide
   Show/Hide
C24H19F3N6O3
 1
1 IC50 = 8 nM
CP0060023
N-[4-methyl-3-[3-[2-(methylamino)pyridin-4-yl]pyridin-2-yl]oxyphenyl]-3-(1,1,2,2-tetrafluoroethoxy)benzamide
   Show/Hide
C27H22F4N4O3
 1
1 IC50 = 9 nM
CP0061157
N-[4-(1,3-benzothiazol-2-yl)-3-fluorophenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C30H31FN6O2S
 1
1 IC50 = 9 nM
CP0037385
4-Methyl-3-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)-N-(2-morpholino-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C29H27F3N6O3
 1
1 IC50 = 10 nM
CP0161871
2-(Methylamino)triazine 59
   Show/Hide
C24H19F3N6O2
 1
1 IC50 = 10 nM
CP0258617
benzimidazole-urea, 17
   Show/Hide
C23H17F4N5O4
 1
1 IC50 = 10 nM
CP0289769
2-(Methylamino)triazine 65
   Show/Hide
C31H35FN8O2
 1
1 IC50 = 13 nM
CP0047967
5-[(2-aminopyrimidin-5-yl)ethynyl]-2-fluoro-N-[2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]benzamide
   Show/Hide
C25H22F4N6O
 1
1 IC50 = 13 nM
CP0254940
(S)-N-(2-(3-Aminopiperidin-1-yl)-5-(trifluoromethyl)phenyl)-5-(2-(2-aminopyrimidin-5-yl)ethynyl)-2-fluorobenzamide
   Show/Hide
C25H22F4N6O
 1
1 IC50 = 13 nM
CP0018963
3-(4-{4-aminofuro[2,3-d]pyrimidin-5-yl}phenyl)-1-[2-fluoro-5-(trifluoromethyl)phenyl]urea
   Show/Hide
C20H13F4N5O2
 1
1 IC50 = 13.49 nM
CP0047966
(S)-5-(2-(2-Aminopyrimidin-5-yl)ethynyl)-2-fluoro-N-(2-(3-(methylamino)piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C26H24F4N6O
 1
1 IC50 = 14 nM
CP0112104
N-[4-methyl-3-[3-[4-(methylamino)-1,3,5-triazin-2-yl]pyridin-2-yl]oxyphenyl]-3-(1,1,2,2-tetrafluoroethoxy)benzamide
   Show/Hide
C25H20F4N6O3
 1
1 IC50 = 16 nM
CP0098896
N-[4-methyl-3-[3-[4-(methylamino)-1,3,5-triazin-2-yl]pyridin-2-yl]oxyphenyl]-3-pyrrol-1-ylbenzamide
   Show/Hide
C27H23N7O2
 1
1 IC50 = 17 nM
CP0047964
5-(2-(2-Aminopyrimidin-5-yl)ethynyl)-2-fluoro-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C25H21F4N5O
 1
1 IC50 = 17 nM
CP0162640
5-(2-(2-Aminopyrimidin-5-yl)ethynyl)-2-methoxy-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C26H24F3N5O2
 1
1 IC50 = 21 nM
CP0212502
N-(5-Cyclohexyl-2-methoxyphenyl)-4-methyl-3-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)benzamide
   Show/Hide
C30H32N6O3
 1
1 IC50 = 22 nM
CP0151244
N-[4-(1,3-benzothiazol-2-yl)-2-fluorophenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C30H31FN6O2S
 1
1 IC50 = 29 nM
CP0111759
2-(Methylamino)pyrimidine 54
   Show/Hide
C29H26ClF3N6O2
 1
1 IC50 = 30 nM
CP0111770
2-(Methylamino)triazine 63
   Show/Hide
C29H30F4N8O2
 1
1 IC50 = 30 nM
CP0075729
3-(2-(2-Aminopyrimidin-5-yl)ethynyl)-4-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C26H24F3N5O
 1
1 IC50 = 30 nM
CP0166275
N-[4-(1,3-benzothiazol-2-yl)-3-chlorophenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C30H31ClN6O2S
 1
1 IC50 = 37 nM
CP0111776
2-(Methylamino)pyrimidine 55
   Show/Hide
C30H29F3N6O2
 1
1 IC50 = 39 nM
CP0111774
2-(Methylamino)pyrimidine 57
   Show/Hide
C29H26F4N6O2
 1
1 IC50 = 40 nM
CP0047962
(R)-5-(2-(2-Aminopyrimidin-5-yl)ethynyl)-N-(2-(3-(dimethylamino)piperidin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluorobenzamide
   Show/Hide
C27H26F4N6O
 1
1 IC50 = 44 nM
CP0015507
2-(4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yloxy)phenyl)benzo[d]thiazole
   Show/Hide
C30H31N5O3S
 1
1 IC50 = 44 nM
CP0285297
2-(Methylamino)triazine 62
   Show/Hide
C28H25F4N7O2
 1
1 IC50 = 53 nM
CP0161870
2-(Methylamino)triazine 61
   Show/Hide
C30H33F3N8O2
 1
1 IC50 = 59 nM
CP0171457
N-(5-Cyclohexyl-2-methoxyphenyl)-4-methyl-3-(3-(2-(methylamino)pyridin-4-yl)pyridin-2-yloxy)benzamide
   Show/Hide
C32H34N4O3
 1
1 IC50 = 62 nM
CP0526660
2-(Methylamino)pyrimidine 53
   Show/Hide
C29H26F4N6O2
 1
1 IC50 = 62 nM
CP0047965
3-(2-(2-Aminopyrimidin-5-yl)ethynyl)-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C25H22F3N5O
 1
1 IC50 = 63 nM
CP0016366
2-(4-(6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-yloxy)phenyl)benzo[d]thiazole
   Show/Hide
C29H28N4O3S
 1
1 IC50 = 72 nM
CP0015511
2-[3-fluoro-4-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]oxyphenyl]-1,3-benzothiazole
   Show/Hide
C30H30FN5O3S
 1
1 IC50 = 88 nM
CP0111761
2-(Methylamino)pyrimidine 52
   Show/Hide
C29H27F3N6O2
 1
1 IC50 = 99 nM
CP0777100
4-methyl-3-(3-(4-(methylamino)-1,3,5-triazin-2-yl)pyridin-2-yloxy)-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
   Show/Hide
C30H30F3N7O2
 1
1 IC50 = 108 nM
CP0135618
N-[4-(1,3-benzothiazol-2-yl)-3-methoxyphenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C31H34N6O3S
 1
1 IC50 = 110 nM
CP0151301
2-(1,3-benzothiazol-2-yl)-5-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]amino]phenol
   Show/Hide
C30H32N6O3S
 1
1 IC50 = 120 nM
CP0069712
N-[4-(6-fluoro-1,3-benzothiazol-2-yl)phenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C30H31FN6O2S
 1
1 IC50 = 235 nM
CP0151259
N-[4-(1,3-benzothiazol-2-yl)-2-methoxyphenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C31H34N6O3S
 1
1 IC50 = 330 nM
CP0091117
N-[4-(5-chloro-1,3-benzothiazol-2-yl)phenyl]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-amine
   Show/Hide
C30H31ClN6O2S
 1
1 IC50 = 510 nM
CP0367808
CHEMBL5090394
   Show/Hide
C24H22ClFN6O3
 1
1 IC50 = 3100 nM
CP0128578
6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-N-[4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]phenyl]quinazolin-4-amine
   Show/Hide
C31H31F3N6O2S
 1
1 IC50 = 3300 nM
CP0034053
US9394309, 147
   Show/Hide
C26H19F5N6OS
 4
1 IC50 ~ 0.45 nM
2 IC50 ~ 0.7 nM
3 Kd = 1.6 nM
4 Kd ~ 1.6 nM
Clinical Information about the Protein
Target 1 ( Angiopoietin 1 receptor (TEK) )
Target Type Clinical trial Target
Disease 4 Target-related Diseases  4
1 Peripheral arterial disease [ICD-11: BD4Z]
2 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
3 Chronic myeloid leukaemia [ICD-11: 2A20]
4 Myelodysplastic syndrome [ICD-11: 2A37]
Clinical Trial Drug(s) 4 Clinical Trial Drugs  4
1 AKB-9778 Phase 2
Peripheral arterial disease
2 CEP-11981 Phase 1
Solid tumour/cancer
3 DCC-2036 Phase 1/2
Chronic myeloid leukaemia
4 Altiratinib Phase 1
Solid tumour/cancer
Discontinued Drug(s) 1 Discontinued Drug  1
1 ARRY-614 Discontinued in Phase 1
Myelodysplastic syndrome